ADVISORY, Dec. 08, 2017 (GLOBE NEWSWIRE) --
What:
Denali Therapeutics Inc. (Nasdaq:DNLI), a biotechnology company focused on the discovery and development of therapies for patients with neurodegenerative disease, will visit the Nasdaq MarketSite in Times Square in celebration of its initial public offering (IPO).
In honor of the occasion, Ryan Watts, Chief Executive Officer, will ring the Opening Bell.
Where:
Nasdaq MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio
When:
Friday, December 8, 2017 – 9:15 a.m. to 9:30 a.m. ET
Denali Therapeutics Inc. Media Contact:
Morgan Warners
202-337-0808 office, 617-872-3655 mobile
mwarners@gpg.com
Nasdaq MarketSite Media Contact:
Emily Pan
(646) 441-5120
emily.pan@nasdaq.com
Feed Information:
Fiber Line (Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
FEC 3/4
SR 13.235
DR 18.295411
MOD 4:2:0
DVBS QPSK
Social Media:
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies, please visit our Facebook page:
http://ift.tt/1ejh9f4.
For photos from ceremonies and events, please visit our Instagram page:
http://ift.tt/1kkvASh
For livestream of ceremonies and events, please visit our YouTube page:
http://www.youtube.com/nasdaq/live
For news tweets, please visit our Twitter page:
http://twitter.com/nasdaq
For exciting viral content and ceremony photos, please visit our Tumblr page:
http://ift.tt/T4ODTg
Webcast:
A live stream of the Nasdaq Opening Bell will be available at:
http://ift.tt/NYKeUb or http://ift.tt/1gnW0EA
Photos:
To obtain a hi-resolution photograph of the Market Open, please go to http://ift.tt/2doY7Jl and click on the market open of your choice.
About Denali Therapeutics Inc.
Denali is a biopharmaceutical company developing a broad portfolio of therapeutic candidates for neurodegenerative diseases. Denali is based in South San Francisco. Denali Therapeutics is committed to developing therapies for neurodegeneration, one of the most significant unmet medical needs of our time. Denali Therapeutics relies on its core principles of identifying and selecting targets based on validated genetic drivers of neurodegeneration, developing medicines that effectively cross the blood-brain barrier and target the brain, and developing and using biomarkers for better patient selection and demonstration of target and pathway engagement of our product candidates in order to succeed in a field that has seen limited progress in the past several decades.
About Nasdaq
Nasdaq (Nasdaq:NDAQ) is a leading global provider of trading, clearing, exchange technology, listing, information and public company services. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 90 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to approximately 3,900 total listings with a market value of approximately $12 trillion. To learn more, visit: http://ift.tt/1ySbdC8
-NDAQA-
Read Again Denali Therapeutics Inc. (Nasdaq: DNLI) to Ring The Nasdaq Stock Market Opening Bell in Celebration of Its IPO : http://ift.tt/2kE1bJyBagikan Berita Ini
0 Response to "Denali Therapeutics Inc. (Nasdaq: DNLI) to Ring The Nasdaq Stock Market Opening Bell in Celebration of Its IPO"
Post a Comment